Immune-engineered stem cells aim for functional cure in type 1 diabetes
Researchers at the ISSCR 2026 meeting report a first-in-human approach using hypoimmune, allogeneic insulin-producing cells that may persist and function without lifelong immunosuppression, potentially moving cell replacement therapies for type 1 diabetes toward a functional cure; durability and scalability remain key questions.